Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 11.3% – Time to Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shot up 11.3% during trading on Friday . The company traded as high as $0.70 and last traded at $0.63. 151,239,068 shares changed hands during mid-day trading, an increase of 431% from the average session volume of 28,475,689 shares. The stock had previously closed at $0.57.

Analyst Ratings Changes

Separately, StockNews.com began coverage on shares of Tonix Pharmaceuticals in a report on Sunday, December 15th. They issued a “sell” rating on the stock.

Tonix Pharmaceuticals Price Performance

The business’s fifty day moving average is $0.20 and its 200 day moving average is $0.49. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $114.30 million, a P/E ratio of -0.01 and a beta of 2.23.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The business had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. As a group, analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.